Board of Directors


Jeani Delagardelle is a Managing Director at New Leaf Venture Partners leading the medical device piece, with 30 years experience in that industry. Jeani also is a Senior Advisor to Delos Capital with a focus on medical device investments. Jeani joined Sprout in August 2000 and became General Partner in July 2001. She was one of the founders of New Leaf upon its spin-out from Sprout in 2005.

Previously, she was a General Partner at Weiss, Peck & Greer Venture Partners where she focused on healthcare/technology investments. Before joining Weiss, Peck & Greer Venture Partners, Jeani spent 15 years in senior marketing, sales, business development and general manager positions in the healthcare industry. Specifically, she was Vice President of Global Marketing for Target Therapeutics and spent nine years with the Medi-tech division of Boston Scientific in several senior management roles. In addition, Jeani served as Director of Business Operations for Roche Laboratories and Director of Global Marketing for Cell Pro, Inc. Jeani attended University of California at Irvine (M.B.A.) and Occidental College (A.B.).


Ryan Drant is the Founder and Managing Partner of Questa Capital, a healthcare-focused venture capital and growth equity investment firm. Ryan previously spent nineteen years at New Enterprise Associates (, where he served as a general partner, Head of Healthcare Investing and a member of the NEA Management Committee. Prior to NEA, he was in the corporate finance group at Alex. Brown & Sons and started his career at Arthur Andersen & Co.

Ryan is a four-time nominee to the Forbes Midas List of top venture capital investors. In addition to Intrinsic Therapeutics, he is currently a director of Bicycle Health, Calyxo, ControlRad, Cortica, Dispatch Health, Eko, Eximis, Medrio and Spine Wave. Ryan also serves on the board of the Medical Device Manufacturers Association and the National Venture Capital Association. He received a Bachelor of Arts degree in Political Science from Stanford University.


Cary Hagan joined Intrinsic in 2011 from Wright Medical, where he served as Senior Vice President, Commercial Operations, for Europe, Middle East and Africa. He began his career at Wright Medical in 1989 and advanced through a series of sales and marketing positions with increasing responsibility. As Senior Director of Biologics, Cary was pivotal in the rapid growth of Wrights Orthobiologics program from “point zero” to market segment leader. Later as Vice President Marketing, Global OrthoRecon, he oversaw a turnaround in Wright’s Hip and Knee growth rates to roughly two times the industry average.

Cary completed undergraduate at Westminster College in Fulton Missouri, with majors in both Business Administration & Economics. He later earned a Master’s in Business Administration at St. Louis University & Webster Universities, with a focus on International Business.


Prior to founding Intrinsic in 1999, Greg Lambrecht was a Vice President of Product Development & Marketing at Stryker, a global orthopedic implant company, where he directed the development and launch of numerous successful orthopedic implants. Greg also held various management positions in product and business development within Pfizer’s Medical Technology Group. The core of his career at Pfizer was implementing a process for inventing and developing new technologies that best met the needs of Pfizer’s physician customers worldwide.

Greg received a Bachelor of Science in Nuclear Engineering from the Massachusetts Institute of Technology in 1990 and returned to the same institution for a Masters Degree in Mechanical Engineering in 1993. Greg holds numerous patents in the fields of gynecology, general surgery, cardiology, and orthopedics.


Josh Makower, MD has served on the board of Intrinsic Therapeutics since 2000 and is a Special Partner on NEA’s healthcare team. In addition to his role at NEA, Josh serves on the faculty of the Stanford University Medical and Engineering Schools as a Professor of Medicine and Bioengineering and is Director and Co-Founder of The Stanford Byers Center for Biodesign.Josh is also the Founder and Executive Chairman of ExploraMed, a medical device incubator that has created 9 companies over the past 25 years. Notable transactions from the ExploraMed portfolio include Acclarent, acquired by J&J in 2009, EndoMatrix, acquired by C.R. Bard in 1997, TransVascular, acquired by Medtronic in 2003, Nuelle, acquired by AyTu Biosciences in 2014, and Neotract acquired by Teleflex in 2017. On-going ExploraMed/NEA ventures include Moximed, Willow Innovations, Revelle Aesthetics, and ExploraMed V. Josh currently serves on the boards of Eargo, Allay Therapeutics, Lungpacer, Revelle Aesthetics, Vesper Medical, Magenta Medical, DOTS Technology Corp., ExploraMed, Intrinsic Therapeutics, Moximed, SetPoint Medical, Willow and Coravin. Josh holds over 300 patents and patent applications for various medical devices in the fields of cardiology, ENT, general surgery, drug delivery, obesity, orthopedics, women’s health, aesthetics, and urology. He received an MBA from Columbia University, an MD from the NYU School of Medicine, and a bachelor’s degree in Mechanical Engineering from MIT, and is a Fellow of the American Institute of Biomedical Engineering and a member of the National Academy of Engineering.


In February 2008 Kevin Sidow began his role as President and Chief Executive Officer for Moximed, Inc. Prior to his current role he was President and CEO for St. Francis Medical Technologies, Inc. Founded in 1997, St. Francis Medical Technologies was a privately held company focused on developing innovative treatments for patients suffering from degenerative spinal disorders. The Company raised a total of $28 million in venture capital. In January 2007, St. Francis Medical Technologies, Inc. was sold for $725 million to Kyphon Inc.

Prior to joining SFMT, Kevin was the Worldwide President of DePuy Inc. As Worldwide President of DePuy; Sidow oversaw the global orthopedic, spine, trauma, and sports medicine businesses and has over 20 years of orthopedic medical device experience. His responsibilities included the combined worldwide reconstructive business (hips, knee, extremities, operating room products, ACE and casting), Spine, Mitek (sports medicine) and Biologics with annual revenue responsibility of over $3 billion. Kevin holds a B.S. in Accounting from West Virginia University.

BRIAN VERRIER – (Chairman of the Board)

Mr. Verrier is currently the President & CEO of Ossio, Inc. Ossio is an early stage company, founded out of Israel, focusing on transformational technology in the Orthopedic Fixation Market.  Over the course of his 27 year career, Brian has held management and leadership positions at all levels.  The majority of Brian’s career has been in the Cardiovascular and Peripheral Vascular markets.  Most recently, Brian was the President of Covidien’s Peripheral Vascular Business Unit, which was eventually acquired in the January 2015 acquisition by Medtronic.  Following Covidien’s 2010 acquisition of Minnesota based ev3, the Peripheral Vascular Business grew from $700m to $1.2b through six strategic acquisitions, as well as realized significant improvement in commercial execution, product development processes and portfolio management. Brian’s principles in leading businesses are centered around innovation and value creation for all stakeholders. 

Brian holds an Economics Degree from the University of Connecticut and currently resides in Massachusetts with his wife Colleen and three children Sean, Ryan and Shea.

If Barricaid is right for you, we can help.

Sign up to receive future updates and information on the Barricaid procedure.
  • This field is for validation purposes and should be left unchanged.